Drug Trial Radar · NCT03758716
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jul 3, 2017
Primary completion
Jan 28, 2019
Study completion Sep 19, 2019
Sponsor
- Lead sponsor
- Fountain Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis
Conditions
- Atopic Dermatitis
Interventions
FB825, FB825-15D11, Anti-CemXDrug
Pharmaceutical form: 20mg/ml solution Route of administration: IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- % Change From Baseline in Total IgETime frame: Day 169
- % Change From Baseline in Allergen-specific IgETime frame: Day 169
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Taiwan University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.